ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2018 Highlights:

300+ Participation (70 Industry: 30 Academia)

10+ Keynote Speakers

50+ Plenary Speakers

20+ Exhibitors

14 Innovative Educational Sessions

5+ Workshops

B2B Meetings

Nanomedicine and drugdelivery will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nano medicine and drug delivery respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as Japan, China, India and other economies in the region. Japan is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.This conference seeks to showcase work in the area of Nanomedicine, Drug Delivery Systems, and nanotechnology, Nanobiothechnology, particularly related to drug delivery.

Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in nanomedicine and drug delivery, where all attendees can interact with the panel followed by a Q&A session.

Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.

Editorial board meeting: Discussing on growth and development of open access Nanomedicine and drugdelivery International Journals and recruiting board members and reviewers who can support the journal.

Over 50+ organizations and international pavilions will be exhibiting at the Nanodelivery 2018 conference and Exhibition. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will see at the Nanodelivery Exhibition, you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The Nanodelivery 2018 has everything you need, all under one roof, saving you both time and money. It is the event you cannot afford to miss!

Sessions/Tracks

The field of Nano Delivery now has pivotal roles in electronics, biology and medicine. Its application can be appraised, as it involves the materials to be designed at atomic and molecular level. Due to the advantage of their size, nanospheres have been shown to be robust drug delivery systems and may be useful for encapsulating drugs and enabling more precise targeting with a controlled release. In this review specifically, we highlight the recent advances of this technology for medicine and drug delivery systems. Nanomaterials range from 10–200 nm up to a few micrometres in size, and include nano- and microparticles, nanotubes and quantum dots.

Nanotechnological devices are made from metals, polymers, lipids and organic substances as well as from macromolecules such as dendrimers, antibodies, micelles, liposomes and nanofibers. Nanomedicine makes use of these nanostructures for diagnostic or therapeutic applications in all fields of medicine, using them for drug delivery, biosensors, neuro-electronic interfaces, in vivo imaging, and cell-specific molecular interactions, where "cell repair machines" could revolutionize medicine and the medical field. As drug delivery systems, nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs. The strength of nanoparticulate drug delivery systems is their ability to alter the pharmacokinetics and biodistribution of drugs.

Nanotechnology for cancer is a field that incorporates the studies related to nanosized particles, their function and behavior with respect to different systems. The tremendous capabilities of nanoparticles have changed the perspective and scope of nanotechnology towards development into an adjuvant field for the remaining fields of life sciences. The role of nanotechnology in the field of pharmaceutics has tremendously changed the way of our understanding about drugs, nanodrugs or the use of nanoparticles as carrier of drug has become the basic fundamental or criteria for the production or design of a drug and advances in nanotechnology.

Nanotechnology is an important field of modern research dealing with design, synthesis, and manipulation of particle structures ranging from approximately 1-100 nm.

Synthesizing nanoparticles for pharmaceutical purposes such as drug preparation can be done in two methods. Bottom up process such as pyrolysis, inert gas condensation, solvothermal reaction, sol-gel fabrication and structured media in which hydrophobic compound such as liposomes are used as bases to mount the drug. Top down process such as attrition / milling in which the drug is chiseled down to form a nanoparticle

The promise of regenerative medicine is truly remarkable. Regenerative medicine is a new branch of medicine that attempts to change the course of chronic disease, in many instances regenerating failing organ systems lost due to age, disease, damage, or congenital defects. The area is rapidly becoming one of the most promising treatment options for patients suffering from tissue failure.

Tissue Engineering and Regenerative Medicine is appealing to scientists, physicians, and lay people alike: to heal tissue or organ defects that the current medical practice deems difficult or impossible to cure.

Theranostic nanomedicine is emerging as a promising therapeutic paradigm. It takes advantage of the high capacity of nanoplatforms to ferry cargo and loads onto them both imaging and therapeutic functions. The resulting nanosystems, capable of diagnosis, drug delivery and monitoring of therapeutic response, are expected to play a significant role in the dawning era of personalized medicine, and much research effort has been devoted toward that goal.

Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices. The pharmaceutical industry is developing new commercial applications that may include advanced drug delivery systems, new therapies, and Nanomaterials for Imaging and Drug Delivery. Another active and very much related area of research is the investigation of toxicity and environmental impact of nanoscale materials, since nanomedicines must be biocompatible for clinical application.

Drug Delivery Conferences attains greater global significance as Drug Delivery plays a significant role in the future of pharmaceutical research Novel drug delivery system method by which a drug is delivered can have a significant effect on its efficacy. Conference includes topics like lipid Polymers to enhance drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods, cyclic dosage, and tunable release of both hydrophilic and hydrophobic drugs. In vitro & in vivo dissolution testing is required to ensure that drug dissolves at a consistent rate from batch to batch of formulated drug product. Improvement of dissolution rate of poorly soluble drugs can be increased by dissolving them in liquid hydrophilic vehicles followed by soaking on highly porous materials. The major part is to deliver an innovative speech on the latest Targeted drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. Pharmacokinetic behavior in drug design and drug development for safety issues arising either as a result of animal toxicity testing or in the clinical program itself

Biopharmaceutics is defined as the study of factors influencing the rate and amount of drug that reaches the systemic circulation and the use of this information to optimise the therapeutic efficacy of the drug products. The process of movement of drug from its site of administration to the systemic circulation is called as absorption. The concentration of drug in plasma and hence the onset of action, and the intensity and duration of response depend upon the bioavailability of drug from its dosage form. Bioavailability is defined as the rate and extent (amount) of drug absorption.Biologic Drugs, or biologic response modifiers, are medications genetically engineered from a living organism, such as a virus, gene or protein, to simulate the body’s natural response to infection and disease. Biologics target proteins, cells and pathways responsible for the symptoms and damage of rheumatoid arthritis and other types of inflammatory arthritis. Biologic response modifiers (biologics for short) are drugs that are genetically engineered from a living organism, such as a virus, gene or protein, to simulate the body’s natural response to infection and disease.

Nanobiotechnology is the intersection of nanotechnology and biology. Nanobiotechnology has multitude of potentials for advancing medical science thereby improving health care practices around the world. Nanomedicine is used to treat diseases by gene therapy. Nano biotechnologies are being applied to molecular diagnostics and several technologies are in development.

Nanoethics is the study ethical and social implications of nanotechnology’s. It is an emerging but controversial field. Nanoethics is a debatable field. As the research is increasing on nanomedicine, there are certain regulations to increase their efficacy and address the associated safety issues. Other issues in nanoethics include areas like research ethics, environment, global equity, economics, politics, national security, education, life extension and space exploration.

The idea that pharmaceutical agents should be delivered specifically to diseased cells holds the promise of a variety of benefits. The promise of individualized medicine is that it is efficient. Targeted drug-delivery allows doctors and patients to benefit from small dosages at just the right place and thus from fewer side effects.

Nanomedicine has therapeutic uses as well. Nanotechnology is capable of delivering medication to the exact location where they are needed, hence lesser side effects. It can also be used to destroy harmful organisms or cancer cells by interrupting their division process. Nanoprobes can be made to generate radiation that could kill bacteria, viruses and cancer cells. Nanotechnology also theoretically allows the mimicking of natural biological processes, e.g. repair of damaged tissues or acting as artificial red blood cells to transport oxygen.

The global market for healthcare nanotechnology is expected to reach USD 196.02 billion by 2020 growing at a CAGR of 12.1%, according to a new study by Grand View Research, Inc. Increasing susceptibility of patients towards chronic diseases such as cardiovascular, neurological, oncology and respiratory diseases coupled with increasing R&D spending opening new application avenues is expected to drive market growth over the next six years. Other drivers of this market include increasing government and private sector R&D aid and new players entering the market to bridge the gap between supply and demand.

Importance & Scope of Nano Delivery:

Researchers are developing a nanoparticle that can be taken orally and pass through the lining of the intestines into the bloodsteam. This should allow drugs that must now be delivered with a shot to be taken in pill form. The researchers have demonstrated the technique with lab mice so far.

Researchers are also developing a nanoparticle to defeat viruses. The nanoparticle does not actually destroy viruses molecules, but delivers an enzyme that prevents the reproduction of viruses molecules in the patients bloodstream. The effectiveness of the technique has been demonstrated in lab tests.

About venue:

Tokyo is Japan's capital and the world's most populous metropolis. It is also one of Japan's 47 prefectures, consisting of 23 central city wards and multiple cities, towns and villages west of the city center. The Izu and Ogasawara Islands are also part of Tokyo. Prior to 1868, Tokyo was known as Edo. A small castle town in the 16th century, Edo became Japan's political center in 1603 when Tokugawa Ieyasu established his feudal government there. A few decades later, Edo had grown into one of the world's most populous cities. With the Meiji Restoration of 1868, the emperor and capital moved from Kyoto to Edo, which was renamed Tokyo ("Eastern Capital"). Large parts of Tokyo were destroyed in the Great Kanto Earthquake of 1923 and in the air raids of 1945.

Today, Tokyo offers a seemingly unlimited choice of shopping, entertainment, culture and dining to its visitors. The city's history can be appreciated in districts such as Asakusa, and in many excellent museums, historic temples and gardens. Contrary to common perception, Tokyo also offers a number of attractive green spaces in the city center and within relatively short train rides at its outskirts.An ancient city that has grown organically rather than according to an imposed plan, Tokyo exhibits a layout that differs radically from the grid-like patterns of cities like Washington, D.C., or Chicago. The streets follow no discernible pattern, though they might approximate a spiderweb, with concentric circles like Meiji-dori intersected by radiating streets like Shinjuku-dori and Yamate-dori. The geographical center is arguably Chiyoda-ku, where the Imperial Palace is located, though Chiyodaku, with its abundant public park space, hardly qualifies as Tokyo's "downtown." No other area qualifies as downtown either; instead, the city has several concentrated "centers," such as Shibuya, Shinjuku, and Ikebukuro. Other hubs include Setagaya, the Ginza, and Ueno.

The Tokyo region is Japan's leading industrial center, with a highly diversified manufacturing base. Heavy industries are concentrated in Chiba, Kawasaki, and Yokohama, while Tokyo proper is strongly inclined toward light industry, including book printing and the production of electronic equipment.

More significantly, perhaps, Tokyo is Japan's management and finance center. Corporations with headquarters or branches or production sites in other parts of the country often have large offices in Tokyo, Marunouchi being the location of many of these. The close relationship between government and business in Japan makes a Tokyo location advantageous if not necessary.

To the north of Marunouchi is Otemachi, where Japan's leading financial institutions and insurance companies are located. Otemachi is also home to NTT, the communications giant. Of course, Tokyo is also the site of the Tokyo Stock Exchange, located in Kabutocho.

Tokyo was particularly affected by an economic boom in Japan in the 1980s when the country emerged as a global financial center rivaling Europe and the United States. The economic upswing led to speculation, and especially to real estate speculation. Land prices soared at the time, as did the value of the yen. The economy leveled out by the early 1990s, but Tokyo real estate remained the most expensive in Japan and held a similar rank on a global scale.

Why to Attend??? :

2nd International Conference and Exhibition on Nanomedicine and Drug Delivery - 2018 which will be the greatest gathering devoted to Nanomedicine and Drug delivery.

• Professionals giving a chief specialized gathering to detailing and finding out about the most recent new era advancements created over the span of time alongside examining their applications.

• Events incorporate intriguing issues introductions from everywhere throughout the world and expert systems administration with enterprises, driving working gatherings and boards.

• Meet Your Objective Business area with people from and around the world focused on getting some answers concerning Pharmaceutics and Nanotechnology , this is the most obvious opportunity to accomplish the greatest accumulation of individuals from wherever all through the World.

• Conduct appears, scatter information, meet with current, make a sprinkle with another item offering, and get name affirmation at this event. Generally acclaimed speakers, the most recent techniques, methodologies, and the most breakthrough updates in Pharmaceutics and Engineering are indications of this meeting.

Nanomedicine Market in Japan:

Nanomedicine is a promising sub-segment in medicine that took off in the 1980s with the first generation of developed nanopharmaceuticals. With the use of nanotechnology, drugs can be delivered in ways not experienced so far.U.S. is a strong actor in this field with many patents having commercialized several nanopharmaceuticals.

The global nanomedicine market was valued at US$50.1 billion in 2011 and is projected to grow to US$96.9 billion in 2016. The share of nanomedicine to the total global pharmaceutical market is estimated at 5.3 percent in 2011 indicating its niche character presently.

In Japan, for various reasons, the nanomedicine market size in terms of the total market is much smaller. A rough estimate shows that the share is between 1 to 2 percent corresponding to approximately US$1 to 2 billion. A limited number of approved Japanese nanodrugs together with a long time until approved foreign products entered the Japanese market have seemingly slowed the market expansion.

Japan = World's 2nd largest pharmaceutical market!

Japan is the 2nd largest pharmaceutical market in the world, marking JPY 10 trillion (USD 84.4 billion) in ethical drug in 2016.

Nikkei Stock Average has been continuously increasing since mid October, 2016.

The government is to ease the regulations to develop new medicines for intractable diseases by shortening 5 years of drug development time.

Japan’s pharmaceutical industry is the world’s second largest market, after U.S., valued at US$112.1 billion in 2012 or 11.6 percent of the world market. Historically, the market has been protected from foreign competition. These days, however, deregulation has prompted investment from abroad and increased the presence of foreign companies. The pharmaceutical industry is one of the few industrial sectors in which Japan has a trade deficit. Japan imports more than two times what it exports. The rapid aging of the population and the weak global competitiveness of domestic companies are contributing factors to the trade deficit.

Japan Nanomedicine Market Size:

There is no market information available on the size of Japan’s nanomedicine market published by any of the large Japanese market research companies. Table 2 below tries to estimate the market size. The global nanomedicine market was estimated to be about 5 percent of the global pharmaceutical market in 2010 and 2011. In case of Japan, this ratio is much lower compared to the global nanomedicine market. A rough estimate indicates that the market size was approximately 1-2 percent of the Japanese pharmaceutical market in 2011-2012, or roughly between US$1 billion – US$2 billion. The drug lag of imported nanopharmaceuticals is one cause of this. Nanomedicines have not been defined in Japan and are regulated within the general framework of the Pharmaceutical Affairs Law (PAL) on a product-by-product basis .

Approved Nanopharmaceutical Products by Application:

As there is no specific definition for drug and device (nanocarrier) combinations, they are regulated as drugs or medical devices according to their main function or purpose.

Pharmaceuticals are classified as nanomedicine by their sizes, i.e. materials in the submicron range.Information on marketed nanopharmaceuticals in Japan comes from various sources including “Current Initiatives in Japan for Nanomedicines”, Kumiko Sakai-Kato, Toru Kawanishi, 2011, National Institute of Health Sciences (NIHS) and Ministry of Health, Labour and Welfare (MHLW) .

Order to reduce the time span from discovery and innovation to commercialization, the importance to establish open user facility networks to promote the integration of dissimilar fields and academic-industry collaboration is emphasized.

It is apparent that the government is aiming at more concrete and speedy results for R&D. Issue-driven innovation based on “exit-oriented” R&D is targeted to impact the competitive power of related industries.

A report by the Japan Science & Technology Agency titled “Japan’s New Science and Innovation Policy – Beyond the Boundaries for Innovation”, published in 2016 (50) lists up the time span for selected target applications of nanomedicine, such as:

Integrated system of drug delivery, diagnosis and treatment (2015-2020)

Implant devices for diagnosis and treatment (2020-2030)

Nano-cell surgery (2020-2030)

3D-imaging in cells (2020-2030)

These are quite ambitious targets showing the directions where R&D will be focused.

In addition to the latest basic plan, there are other signals that the government is increasingly prioritizing innovative medicine. For instance, The Ministry of Health, Labour and Welfare will jointly with the European Union (EU) promote the development of nano-based block copolymer micelles. Together with European Medicines Agency (EMA) the ministry has released a reflection paper (February 2013) emphasizing that such micelles are able to preferentially accumulate in solid tumors (51).

Nanomedicine – Research and Development in Japan:

University of Tokyo

Hokkaido University

Osaka Prefecture University

Osaka University

Tohoku University

National Institute for Materials Science

The Japanese Nanomedicine Industry:

Nanomedicine start-ups and small-medium enterprises have driven the innovation process, not only in US and Europe but also in Japan. The commercialization of nanopharmaceuticals have basically followed three types of business models , such as:

Development of a nanotechnology platform used to add value to second-party products

Development of nanotechnology-improved pharmaceuticals or medical devices

The majority of start-ups has adopted the third business model utilizing nanotechnology to develop own proprietary product pipelines. Often such companies introduce new or standard drugs that are delivered with a drug delivery system. Then they try to team up with pharmaceutical companies that take the products through the clinical trials.

NanoCarrier Co., Ltd.

LTT Bio-Pharma Co., Ltd.

Mebiopharm Co., Ltd.

Nippon Kayaku Co., Ltd

Kowa Company Ltd.

Mitsubishi Tanabe Pharma Corporation

Taisho Pharmaceutical Co., Ltd.

Astellas Pharma Inc

Kaken Pharmaceutical Co., Ltd.

Drug Delivery Devices market in Japan:

Japan has one of the world’s most advanced healthcare facilities. The healthcare administration in Japan is also becoming a model for many developing nations.

The report details several factors driving the market, some of which are listed below.

The global drug delivery system market size was valued at USD 379.2 Billion in 2015. Growing efforts towards formulating dosage forms that would help in maximizing the bioavailability of the drug at the target site while increasing the patient convenience are driving the global market growth. The introduction of the novel drug delivery systems such as subdermal implants that are available in different forms such as rings and patches are expected to aid in the industry growth.

The evolution of the drug delivery systems is directly attributed to changing preferences by patients as well as healthcare professionals. A few of the many advancements include-

The global tissue engineering and cell therapy market stood at nearly $9.9 billion in 2014 and is forecast to see an annual average growth rate of 21% to reach a value of around $73 billion by 2025.

Tissue Engineering is a process involving in-vitro development of tissues or organs. It is done to replace or support the function of defective or injured body part. Tissue engineering involves the application of biology and engineering for innovation of tissue substitutes that can maintain, restore and improve the function of ruptured human tissue. Products developed by this procedure are efficient and durable. Tissue engineering is gaining its popularity in various areas such as burn treatment or wound care, neurology products, orthopedics, urological products and others. On the basis of type of material used, tissue engineering and regeneration market can be segmented into synthetic, genetically modified and biological materials.

The global regenerative medicines market is anticipated to achieve USD 50.11 billion by 2021, registering a CAGR of 12.7% during the period of 2015-2021. On the back of expanding demand for bone and joint reconstructive surgeries within the nation, North America with the most shares in global regenerative dominated the market followed by Europe in 2015. Further, it's projected that by 2019 Europe might surpass the North America market in the field of stem cell and regenerative medicine. Eastern and Western Europe are anticipated to demonstrate extended request in light of the fact that the requirement for transplants through regenerative drugs will be expanding for several applications in coming future. Asia-Pacific countries are required to show up-surged request amid 2015-2021. In addition to that, Asia-Pacific transforming into one of the prime mainlands in providing regenerative medicines on bone and joint in nations like India, China, Japan and South Korea are anticipated to give a lift to the stem cell market within these countries .

Pharmaceutical Regulations in Japan:

Manufacturing, importation, and sales of drugs and medical devices are regulated by the Pharmaceutical Affairs Law (PAL) of Japan.

All manufacturing and marketing applications in Japan for drugs and devices are reviewed by the Pharmaceutical and Medical Devices Agency (PMDA) . All applications are thoroughly reviewed before PMDA submits an approval recommendation to the Ministry of Health, Labour and Welfare (MHLW).

Under PAL, when importing to Japan and selling pharmaceutical products manufactured in other countries, a license for marketing authorization is required. The Marketing Authorization Holder (MAH) will be the owner of the license for marketing authorization.

The MAH must be based in Japan and can be the foreign company’s Japan office, the foreign company’s distributor, or an independent third party acting as the Designated Marketing Authorization Holder (DMAH).

To import and market a new drug in Japan, an approval (marketing approval) will be necessary. And the approval must be held by the Marketing Authorization Holder.

A foreign manufacturer intending to manufacture drugs in foreign countries and export them to Japan, is required to be accredited by MHLW as an “Accredited Foreign Manufacturer” (84). And it is necessary to obtain accreditation for each foreign factory location at which pharmaceuticals for export are manufactured.

The appointed MAH will be responsible for the labelling and advertising of the pharmaceuticals in Japan. As stipulated in PAL, the manufacturer’s/seller’s address, name of product, production indication, name of ingredients, expiration, etc., must be printed on the container of drugs.

Overall research in various disciplines:

The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region. In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region. China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.

Major Nano Delivery Associations around the Globe:

American Nano Society

European Biotechnology Thematic Network Association

Society for Biomaterials

Nano Canadian Society

American Academy of NanoMedicine

American Association for the Advancement of Science

Nanometer-Scale Science and Technology Division of the American Vaccum Society

NanoScience and Technology Institute

ASME NanoTechnology Institute

Foresight Nanotech Institute

International Association of NanoTechnology

The Institute of NanoTechnology

Microscopy Society of America

Nano Business Alliance

European NanoTechnology Gateway

Scottish Center for NanoTechnology in Construction Materials

Royal Society-NanoTechnology and NanoScience

Czech NanoTechnology Industries Association

Erwin Schrodinger Society for NanoSciences

Innovationsallianz Carbon NanoTubes

NanoTechnologies for Tommorow's Society

American Association for the Advancement of Science

Companies involved in Nano Delivery:

USA

Oncolytics Biotech

Bristol-Myers Squibb

GlaxoSmithKline

Bend Research

Pfizer

BioDelivery Sciences

GE Healthcare

Mallinckrodt plc

Nanosphere Inc., USA

Pfizer Inc., USA

Merck & Co Inc., USA

Celgene Corporation, USA

CombiMatrix Corporation, USA

Abbott Laboratories

Many Major companies in the Nano Delivery market.

Global

PolyActivaUnilife

Mati Therapeutics

Formac Pharmaceuticals

Battelle

Toxikon

Novartis

Welcome Message

Past Conference Report

NanoDelivery 2017

Nanodelivery 2017 Report

Held in Osaka, Japan, the International Conference and Exhibition on Nanomedicine and Drug Delivery was an unprecedented event, Organized by Conference Series LLC and supported by Controlled Release society, European society for biomaterials, Nanotechnology World Association and Australian Nanotechnology Networks.

Nanodelivery 2017 was held during May 29-31, 2017 at Hotel Hyatt Regency Osaka; Japan with the theme “Challenges and Innovations in Nanomedicine and Drug Delivery Research” drew benevolent response and agile participation from the Academicians, Scientists, Professors, Chairman’s, CEOs, Presidents, Directors, students, around the globe in the fields of Nanomedicine and Drug Delivery systems, who made this event successful. It also provided invaluable networking opportunity, deploying the foundation for new research endeavors and development projects.

The meeting was carried out through varied sessions, in which the discussions were held on the following major scientific tracks:

With the grand success of Nanodelivery 2017, Conference Series LLC is proud to announce the "2nd International Conference and Exhibition on Nanomedicine and Drug Delivery " to be held during May 14-16, 2018 at Tokyo, Japan.

Be a member and support us

Follow us

Authorization Policy

By registering for the conference you grant permission to Conference Series LLC Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.